Ultrasound Guided Serratus Anterior Versus Erector Spinae Block in Pain Alleviation in Acute Herpes Zoster

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-05

Study Completion Date

2025-04-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acute herpes zoster pain is very severe . Conventional analgesics may be of no value. Regional blocks may play a role

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Erector Spinae Block Versus Thoracic Paravertebral Block for Acute Thoracic Herpes Zoster

NCT04656821

Acute Thoracic Herpes Zoster Erector Spinae Plane Block Thoracic Paravertebral Block +1 more

UNKNOWN PHASE4

Ultrasound-Guided Erectro Spinae Plane Block Versus Stellate Ganglion Block for Patients With Upper Limb Acute Herpes Zoster Pain.

NCT06307444

Acute Herpes Zoster Pain Managment

COMPLETED NA

Comparison Between the Efficacy of Ultrasound-guided Erector Spinae Plane Block and Conventional Treatment for Pain Management in Patients With Post-herpetic Neuralgia

NCT07256145

Post-Herpetic Neuralgia

RECRUITING NA

Rhomboid Intercostal and Subserratus Plane Block Versus Paravertebral Block for Thoracic Herpes Zoster

NCT06751680

Thoracic Herpes Zoster

COMPLETED NA

Erector Spinae Plane Block in Post-herpetic Neuralgia

NCT04546334

Postherpetic Neuralgia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Herpes Zoster Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

800 mg acyclovir, 5 times / day, orally administered, for one week, acetaminophen 1000 mg per day, topical calamine lotion)

Group Type NO_INTERVENTION

No interventions assigned to this group

Erector spinae group

800 mg acyclovir, 5 times / day, orally administered, for one week, acetaminophen 1000 mg per day, topical calamine lotion)+ 25 ml bupivacaine 0.25% plus 8 mg dexamethasone

Group Type ACTIVE_COMPARATOR

ultrasound guided erector spine block

Intervention Type PROCEDURE

Ultrasound guided thoracic erector spinae block

Serratus anterior group

800 mg acyclovir, 5 times / day, orally administered, for one week, acetaminophen 1000 mg per day, topical calamine lotion)+ 25 ml bupivacaine 0.25% plus 8 mg dexamethasone

Group Type ACTIVE_COMPARATOR

Serratus anterior block

Intervention Type PROCEDURE

Ultrasound guided serratus anterior block

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ultrasound guided erector spine block

Ultrasound guided thoracic erector spinae block

Intervention Type PROCEDURE

Serratus anterior block

Ultrasound guided serratus anterior block

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult population between 30 and 75 years old.
* Unilateral painful thoracic herpetic eruption of less than one week duration.
* VAS more than or equal 4, persistent pain in spite of proper antiviral and analgesic therapy, (800 mg oral acyclovir, 5 times per day, for one week), pregabalin 300 mg per day, acetaminophen 1000 mg per day, topical calamine lotion).

Exclusion Criteria

* Diabetic patients.
* Painful herpetic eruptive vesicles more than one week.
* Abdominal herpetic eruptions.
* Non-compliant on anti-viral (bulbar palsy for example).
* Co-malignancy or radiotherapy.
* Steroid therapy \> 5 mg prednisolone or its equivalent.
* Infections or hematoma at site of injection.
* Coagulopathy (chronic kidney or liver disease, clopidogrel use).

Minimum Eligible Age

30 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No